[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Joshua Aiello, Principal Accounting Officer reported a routine withholding transaction related to vested restricted stock units. On 09/17/2025 he had 203 shares of Orchestra BioMed Holdings, Inc. (OBIO) disposed of at $2.46 per share under transaction code F(1), which the filer explains represents shares withheld to satisfy tax withholding obligations upon vesting of restricted stock units. The filing shows 19,126 shares beneficially owned following the transaction, held directly. The form is signed by an attorney-in-fact on behalf of the reporting person on 09/19/2025. No market sale occurred according to the explanation.

Positive

• Reporting person retains direct ownership of 19,126 shares after the withholding transaction
• Transaction was administrative (tax withholding for RSU vesting) and no market sale occurred per the filer

Negative

• 203 shares disposed to satisfy tax withholding obligations, reducing the reporting person's share count
• Transaction price $2.46 reflects the valuation used for the withholding, which may be below recent market levels (if applicable)

Insights

Securities Analyst

TL;DR: Routine insider withholding for taxes; minimal market impact and retains sizable direct ownership.

This Form 4 documents a standard tax-withholding disposition of 203 shares at $2.46 tied to RSU vesting, coded F(1). Such transactions are administrative and do not reflect an open-market sale; the filing explicitly states no shares were sold in the market. The reporting person retains 19,126 shares direct, indicating continued equity alignment with shareholders. For investors, this is a neutral disclosure with limited informational content beyond confirming RSU vesting and resulting ownership level.

Corporate Governance Expert

TL;DR: Administrative tax withholding on vested RSUs; disclosure meets Section 16 reporting requirements.

The statement clarifies the nature of the transaction as tax-related withholding rather than discretionary divestiture. The presence of an attorney-in-fact signature suggests procedural filing assistance. The report identifies the reporting person as Principal Accounting Officer and a director, which means ongoing insider status and required SEC reporting. This is a routine governance disclosure and is not material on its own.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aiello Joshua

(Last) (First) (Middle)

C/O ORCHESTRA BIOMED HOLDINGS, INC.

150 UNION SQUARE DRIVE

(Street)

NEW HOPE PA 18938

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share ("Common Stock")	09/17/2025		F(1)		203	D	$2.46	19,126	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units. No shares were sold in the market as a result of the vesting of these restricted stock units and the satisfaction of tax withholding obligations.

	/s/ Andrew Taylor, Attorney-in-Fact	09/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Joshua Aiello report on the Form 4 for OBIO?

The Form 4 reports that 203 shares were disposed on 09/17/2025 at $2.46 per share as tax withholding related to vested restricted stock units.

Does the Form 4 indicate an open-market sale by the insider?

No. The filer explicitly states no shares were sold in the market; the disposition represents shares withheld to satisfy tax obligations.

How many OBIO shares does the reporting person own after the transaction?

The filing shows 19,126 shares beneficially owned following the reported transaction, held directly.

What is the relationship of the reporting person to Orchestra BioMed?

The reporting person is identified as a Director and Officer with the title Principal Accounting Officer.

Who signed the Form 4 and when?

The Form 4 was signed by /s/ Andrew Taylor, Attorney-in-Fact on 09/19/2025.